Shigellosis
📧 Sign up to get email alerts when something new happens for Shigellosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-22Clinical Trial Results: A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants [Phase 1, Phase 2]
Phase 1/2 trial results for the GVGH altSonflex1-2-3 vaccine targeting diarrhoea caused by Shigella, assessing safety and immune responses i…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine [Phase 2]
A Phase 2 human challenge trial update evaluating protection from LimmaTech Biologics' Shigella tetravalent bioconjugate vaccine. The study …
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Clinical Trial of the S. Flexneri-S. Sonnei Bivalent Conjugate Vaccine [Phase 3]
Phase 3 clinical trial update for a bivalent Shigella vaccine (Shigella flexneri and Shigella sonnei) shows the study is currently active bu…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: The Impact of Shigellosis and Recommended Treatment in Children [Phase 2]
A Phase 2 clinical trial in children is recruiting to evaluate the impact of Shigellosis and the recommended treatment approach for infectio…
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants. [Phase 2]
A Phase 2 study updating safety and immunogenicity data for the Shigella4V2 bioconjugate vaccine in 9-month-old infants has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-02-02Clinical Trial Update: Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122 [Phase 1]
Phase 1 study of the Shigella-ETEC vaccine strain CVD 1208S-122 (CVD 31000) completed and results have been posted.
-
CLINICAL_TRIALS trial_result · 2026-01-30Clinical Trial Update: A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants [Phase 2]
Phase 2 study evaluating the immune response and safety of a multicomponent Shigella vaccine to prevent shigellosis in infants; the trial ha…
-
CLINICAL_TRIALS trial_result · 2026-01-06Clinical Trial Update: Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children [Phase 2]
Clinical Trial Update describing the long-term immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African children in a Phase 2 study…
-
CLINICAL_TRIALS trial_result · 2025-12-04Clinical Trial Update: A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants [Phase 1]
A Phase 1 study completed evaluating the safety and immune responses of the GVGH altSonflex1-2-3 vaccine against Shigellosis in adults, chil…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults [Phase 1]
A first-in-human Phase 1 dose-escalation study evaluating safety and immunogenicity of Inventprise's Shigella-04 vaccine in healthy young ad…
-
CLINICAL_TRIALS trial_result · 2025-08-19Clinical Trial Update: Tebipenem Trial in Children With Shigellosis [Phase 2]
A Phase 2 trial evaluating tebipenem in children with shigellosis is currently listed as active but not recruiting on ClinicalTrials.gov.
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old [Phase 2]
Phase 2 clinical trial evaluating safety and efficacy of ShigETEC, a live attenuated oral vaccine, to prevent Shigella and Enterotoxigenic E…
-
CLINICAL_TRIALS trial_result · 2025-06-15Clinical Trial Update: Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis [Phase 1, Phase 2]
Clinical trial update on the safety and efficacy of ShigActive, a bacteriophage product, in a human experimental model of Shigellosis (Phase…
-
CLINICAL_TRIALS trial_result · 2025-04-24Clinical Trial Update: Phase 2 Shigella Vaccine and Challenge [Phase 2]
Phase 2 trial of a Shigella vaccine has completed and results have been posted. The study was sponsored by the National Institute of Allergy…
-
CLINICAL_TRIALS research · 2025-03-13Clinical Trial Update: Shigella Sonnei 53G Human Infection Study in Kenyan Adults [Phase 1]
Phase 1 human infection study of Shigella Sonnei 53G in Kenyan adults is currently recruiting, sponsored by the University of Oxford.
-
FDA approval · 2025-02-21FDA Approved: SULFAMETHOXAZOLE AND TRIMETHOPRIM — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application from Prasco Laboratories for sulfamethoxazole and trimethoprim, granting approval of a generic p…
-
CLINICAL_TRIALS trial_result · 2025-01-31Clinical Trial Update: Controlled Human Infection Model Challenge/Rechallenge [Phase 1]
Phase 1 trial update for a controlled human infection model using challenge/rechallenge design in Shigellosis; the study is completed with r…
-
CLINICAL_TRIALS research · 2025-01-14Clinical Trial Update: Enterics for Global Health (EFGH)
Clinical trial update for Enterics for Global Health (EFGH) indicates the study involving Shigella in children is currently not recruiting.
-
CLINICAL_TRIALS trial_result · 2024-11-07Clinical Trial Update: InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and Zambia [Phase 1]
Phase 1 clinical trial update for InvaplexAR-Detox and DmLT Adjuvant conducting recruitment in the Netherlands and Zambia for shigellosis an…
-
CLINICAL_TRIALS trial_result · 2024-07-30Clinical Trial Update: A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating safety, immunogenicity, and optimal dosing of a new Shigella vaccine in Kenyan infants has completed.
-
FDA approval · 2024-06-24FDA Approved: SULFAMETHOXAZOLE AND TRIMETHOPRIM — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for sulfamethoxazole and trimethoprim by Prasco Laboratories. This action confirms the approval of t…
-
CLINICAL_TRIALS trial_result · 2024-05-20Clinical Trial Update: Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine [Phase 2]
A Phase 2 clinical trial evaluating responses to vaccination with Shigella vaccine CVD 30000 has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2024-04-23Clinical Trial Update: A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a [Phase 2]
Phase 2 trial evaluating safety and immunogenicity of a Shigella vaccine (SF2a-TT15) completed.
-
CLINICAL_TRIALS trial_result · 2023-06-07Clinical Trial Update: Ciprofloxacin Versus Azithromycin for Children Hospitalised With Dysentery [Phase 4]
A phase 4 trial comparing ciprofloxacin to azithromycin for children hospitalized with dysentery due to Shigella has completed.
-
CLINICAL_TRIALS trial_result · 2022-01-11Clinical Trial Update: Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years [Phase 3]
Phase 3 clinical trial update evaluating efficacy, immunogenicity, and safety of a bivalent Shigella vaccine in children aged 6 months to 5 …